Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Jan 20;95(2):669-74.
doi: 10.1073/pnas.95.2.669.

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity

Affiliations

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity

P S Chowdhury et al. Proc Natl Acad Sci U S A. .

Abstract

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas, and several other types of human cancers. Because among normal tissues, mesothelin is present only on mesothelial cells, it represents a good target for antibody-mediated delivery of cytotoxic agents. In the present study mice were immunized with an eukaryotic expression vector coding for mesothelin. When high serum antibody titers were obtained, a phage display library was made from the splenic mRNA of these mice. After three rounds of panning on recombinant mesothelin, a single-chain Fv (scFv)-displaying phage was selected that bound specifically to recombinant mesothelin and mesothelin-positive cells. The scFv was used to construct an immunotoxin by genetically fusing it with a truncated mutant of Pseudomonas exotoxin A. The purified immunotoxin binds mesothelin with high affinity (Kd 11 nm), is stable for over 40 hr at 37 degrees C and is very cytotoxic to cells expressing mesothelin. It also produces regressions of tumors expressing mesothelin. This combination of selective cytotoxicity, high activity, and stability makes the immunotoxin a good candidate for development as a therapeutic agent. This work also shows that DNA immunization can be used to isolate and clone antibodies against epitopes present on human proteins in their native conformation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phage displaying SS scFv bind specifically to mesothelin (amino acids 291–606) coated ELISA wells in a dose-dependent manner. Phage were exposed to wells coated with mesothelin, p55, BSA, and streptavidin or to uncoated wells. Bound phage was detected as described in Materials and Methods.
Figure 2
Figure 2
Epitopes for SS scFv and K1 are different. Mesothelin-coated wells were incubated with various dilutions of SS scFv or K1 scFv phage in the presence or absence of mAb K1 at 1 μg/ml. Bound phage was detected as mentioned in Materials and Methods.
Figure 3
Figure 3
Binding of SS scFv phage to mesothelin positive and negative cells as detected by immunofluorescence. (A and B) NIH 3T3 K20 cells. (C and D) NIH 3T3 cells. A and C are phase contrast, and B and D are immunofluorescence pictures. All cells were exposed to SS scFv phage as described in Materials and Methods. Binding of anti-Tac phage to both the cell lines was tested and found to be negative (data not shown).
Figure 4
Figure 4
Stability of SS scFv-PE38 at 37°C. SS scFv-PE38 (10 μg/ml) was incubated at 37°C for up to 40.5 hr, and then its cytotoxic activity was measured. The % of initial activity remaining after various periods of incubation is shown.
Figure 5
Figure 5
Anti-tumor effect of SS scFv-PE38 in nude mice. Groups of five animals were injected with 1.5 × 106 A431 K5 cells on day 0. On day 5, tumors reached a size of 50 mm3. Animals were treated intravenously on days 5, 7, and 9 with 2.6 μg (⧫) or 4.3 μg (□) of SS scFv-PE38 in DPBS containing 0.2% human serum albumin. Control groups received either the carrier alone (○) or 3 μg anti-Tac(scFv)-PE38 (•). No death or toxicity was observed at these doses.

Similar articles

Cited by

References

    1. Press O W, Eary J F, Appelbaum F R, Martin P J, Badger C C, Nelp W B, Glenn S, Butchko G, Fisher D, Porter B. N Eng J Med. 1993;329:1219–1224. - PubMed
    1. Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, Mellstedt H. J Clin Oncol. 1997;15:1567–1574. - PubMed
    1. Chang K, Pai L H, Batra J K, Pastan I, Willingham M C. Cancer Res. 1992;52:181–186. - PubMed
    1. Chang K, Pai L H, Pass H, Pogrebriak H W, Tsao M-S, Pastan I, Willingham M C. Am J Surg Pathol. 1992;16:259–268. - PubMed
    1. Chang K, Pastan I. Proc Natl Acad Sci USA. 1996;93:136–140. - PMC - PubMed

MeSH terms

Associated data

LinkOut - more resources